FH and hereditary leiomyomatosis and renal cell cancer: Although these adaptive mutations have not been confirmed in HLRCC patient genomic data and would need to be validated in vivo to fully confirm the impact on them in disease initiation and progression, these results are supportive of a multi-step tumorigenesis process in FH-deficient cells.